Editorial
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World Journal of Experimental Medicine. Aug 30, 2018; 8(1): 1-7
Published online Aug 30, 2018. doi: 10.5493/wjem.v8.i1.1
Predictive markers of endocrine response in breast cancer
Duniya Mosly, Arran Turnbull, Andrew Sims, Carol Ward, Simon Langdon
Duniya Mosly, Arran Turnbull, Andrew Sims, Applied Bioinformatics of Cancer, University of Edinburgh Cancer Research Centre, MRC Institute of Genetics and Molecular Medicine, Edinburgh EH4 2XR, United Kingdom
Duniya Mosly, Arran Turnbull, Carol Ward, Simon Langdon, Cancer Research UK Edinburgh Centre and Division of Pathology Laboratory, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, United Kingdom
Carol Ward, the Royal (Dick) School of Veterinary Studies and Roslin Institute, University of Edinburgh, Easter Bush, Roslin, Midlothian, Edinburgh EH25 9RG, United Kingdom
Author contributions: All authors contributed their views in this editorial; all authors read and agreed to the final manuscript.
Conflict-of-interest statement: None.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Simon Langdon, PhD, Reader (Associate Professor), Cancer Research UK Edinburgh Centre and Division of Pathology Laboratory, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, United Kingdom. simon.langdon@ed.ac.uk
Telephone: +44-131-5371763 Fax: +44-131-5373159
Received: June 29, 2018
Peer-review started: June 30, 2018
First decision: July 17, 2018
Revised: July 26, 2018
Accepted: August 4, 2018
Article in press: August 4, 2018
Published online: August 30, 2018
Abstract

Ongoing clinical and research efforts seek to optimise the use of endocrine therapy in the treatment of breast cancer. Accurate biomarkers are needed that predict response for individual patients. The presence of the estrogen receptor (ER) as the direct (for tamoxifen and fulvestrant) or indirect (for aromatase inhibitors) target molecule for endocrine therapy remains the foremost biomarker and determinant of response. However, ER expression only poorly predicts outcome and further indicators of response or resistance are required. The development and application of molecular signature assays such as Oncotype Dx, Prosigna, Mammaprint and Endopredict have provided valuable information on prognosis and these are being used to support clinical decision making on whether endocrine therapy alone alongside surgery is sufficient for ER-positive early stage breast cancers or whether combination of endocrine with chemotherapy are also warranted. Ki67, the proliferation marker, has been widely used in the neo-adjuvant (pre-operative) setting to help predict response and long term outcome. Gene expression studies within the same setting have allowed monitoring of changes of potential predictive markers. These have identified frequent changes in estrogen-regulated and proliferation genes. Specific molecules such as mutant ER may also prove helpful biomarkers in predicting outcome and monitoring response to treatment.

Keywords: Estrogen, IL6ST, Biomarker, Breast cancer, Predictive

Core tip: The expression level of estrogen receptor remains the major determinant of response for endocrine therapy in breast cancer. Molecular signatures provide increasing confidence for helping identify breast cancers for which endocrine therapy alone is likely to be sufficient. Estrogen and proliferation related genes have come to the fore in many of the molecular signatures. In neo-adjuvant studies, Ki67 expression at baseline and after 2 wk treatment can provide useful prognostic and predictive information. Neo-adjuvant studies continue to seek new markers that relate to tumor response.